A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis
Phase of Trial: Phase III
Latest Information Update: 27 Nov 2017
At a glance
- Drugs Roxadustat (Primary)
- Indications Anaemia
- Focus Registrational; Therapeutic Use
- Acronyms ALPS
- Sponsors Astellas Pharma BV
- 21 Nov 2017 Status changed from active, no longer recruiting to completed.
- 21 Nov 2017 This trial has been completed in Spain (End date: 2017-11-01).
- 10 Jun 2017 Biomarkers information updated